(PDF) The Implications of Model-Informed Drug Discovery and

The Implications of Model-Informed Drug Discovery and Development for Tuberculosis

Drug Discovery Today - Netherlands

doi 10.1016/j.drudis.2016.09.004

Full Text

Abstract

Available in full text

Categories

Date

March 1, 2017

Authors

Morris Muliaditan

Geraint R. Davies

Ulrika S.H. Simonsson

Stephen H. Gillespie

Oscar Della Pasqua

Publisher

Elsevier BV

Related search

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

CPT: Pharmacometrics and Systems Pharmacology

Cardiovascular Medicine

English

The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets

Cold Spring Harbor perspectives in medicine

Molecular Biology

English

Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development

Clinical Pharmacology and Therapeutics

English

The Consequences of ‘Brexit’ for Drug Discovery and Development, and the Regulatory Implications

Expert Opinion on Drug Discovery

English

Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Journal of Clinical Pharmacology

English

Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis

Frontiers in Microbiology

English

Discovery and Characterization of the Tuberculosis Drug Lead Ecumicin

Organic Letters

Organic Chemistry

Theoretical Chemistry

English

Model Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients

CPT: Pharmacometrics and Systems Pharmacology

Cardiovascular Medicine

English

Alternative Dosing Regimens for Atezolizumab: An Example of Model-Informed Drug Development in the Postmarketing Setting

Cancer Chemotherapy and Pharmacology

Cancer Research

English